Other antiviral compounds

Aus coViki
Wechseln zu: Navigation, Suche
PHA antivirals by mechanism

32297571 2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus

32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
32429580 2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
32423027 2020. COVID-19: An Update About the Discovery Clinical Trial.
32023685 2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
32432977 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
32501538 2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
32495848 2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.

32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
32176361 2020. Potentially repurposing adamantanes for COVID-19
32495926 2020. Does amantadine have a protective effect against COVID-19?
32436995 2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
32571606 2020. Amantadine Treatment for People with COVID-19.
32542661 2020. Use of amantadine in a patient with SARS-CoV-2.

32442105 2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.

32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.

32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients
32479865 2020. Lack of antiviral activity of darunavir against SARS-CoV-2.

32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data

32374457 2020. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19

32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections

32227493 ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19

16621037 2006. (x)Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin

32344308 2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2

32517353 2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.

32387040 ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
32420958 2020. Sofosbuvir as a potential option for the treatment of COVID-19.
32419838 2020. Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment.
32518317 2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.

32513797 2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.

32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
32205350 2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses

32344167 ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study

Anti HCV nucleotides
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
32253226 ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

beta ketoamides
32045235 ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment

some lipids
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?

20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus

32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses

Meine Werkzeuge